Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3882761 | 0.85 | NPC1 (0.31) | NPC1RAB9AKMT2A | |
| SCHEMBL3879047 | 0.84 | HRH3 (0.36) | CHEK1NPC1RAB9AKMT2A | |
| SCHEMBL3880391 | 0.81 | CNR2 (0.38) | — | |
| SCHEMBL3879097 | 0.80 | PIK3CA (0.34) | PIK3CANPC1RAB9AKMT2A | |
| SCHEMBL3891441 | 0.80 | NPC1 (0.38) | NPC1RAB9AKMT2A | |
| SCHEMBL3880968 | 0.79 | NPC1 (0.32) | NPC1RAB9AKMT2A | |
| SCHEMBL3882370 | 0.79 | CNR2 (0.41) | KMT2A | |
| SCHEMBL3879442 | 0.79 | APP (0.40) | NPC1RAB9AKMT2A | |
| SCHEMBL3880226 | 0.78 | GRM5 (0.39) | PIK3CANPC1RAB9A | |
| SCHEMBL3880276 | 0.78 | HRH3 (0.39) | NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1858900-B1 | FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LTD (GB) | 2009-01-07 | — | — | EP | claimed |
| US-20080161289-A1 | Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor | GLAXO GROUP LIMITED | 2008-07-03 | — | — | US | claimed |
| EP-1858900-B1 | FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LTD (GB) | 2009-01-07 | — | — | EP | disclosed |
| US-20080161289-A1 | Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor | GLAXO GROUP LIMITED | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161289-A1 | Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor | HRH3, HRH4, HRH2 | CHEK1 3799/4885PIK3CA 4145/4885NPC1 1741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.